Request Demo
Last update 22 Dec 2025
MT-1013
Last update 22 Dec 2025
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms MT 1013, MT1013 |
Target |
Action antagonists |
Mechanism PTH1R antagonists(Parathyroid hormone receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
9
Clinical Trials associated with MT-1013CTR20253524
[14C]MT1013在中国成年男性健康参与者和慢性肾脏病维持性血液透析合并继发性甲状旁腺功能亢进参与者体内的物质平衡研究
[Translation] Study on the balance of [14C]MT1013 in healthy Chinese adult male participants and participants with chronic kidney disease undergoing maintenance hemodialysis and secondary hyperparathyroidism
NCT07122401
A Multicenter, Randomized, Double-blind, Double-dummy, Phase III Study to Evaluate the Efficacy and Safety of MT1013 Versus Cinacalcet as Active Control in Secondary Hyperparathyroidism Patients on Maintenance Dialysis
NCT06690242
A Multicenter, Randomized,Positive Controlled, and Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of MT1013 Injection in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Undergoing Maintenance Hemodialysis
100 Clinical Results associated with MT-1013
Login to view more data
100 Translational Medicine associated with MT-1013
Login to view more data
100 Patents (Medical) associated with MT-1013
Login to view more data
100 Deals associated with MT-1013
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hyperparathyroidism, Secondary | Phase 3 | China | 25 Sep 2025 | |
| Hypercalcemia | Phase 2 | United States | - | |
| Hypercalcemia | Phase 2 | China | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 114 | kjwymelfxp(oensivngox) = adpidnuzgf oqlgifluvp (waftbvqarq ) View more | Positive | 06 Nov 2025 | |||
kjwymelfxp(oensivngox) = ummienswft oqlgifluvp (waftbvqarq ) View more | |||||||
Phase 2 | 33 | rdavlowuar(rtkkyrnizv) = uaxjassxlq bmpyhabrrl (geavqimqto ) View more | Positive | 06 Nov 2025 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free